A new drug for pancreas cancer may be a game changer, Elizabeth Tracey reports
About this episode
The episode discusses a new drug, Daraxonrasib, that significantly improves survival rates for pancreas cancer patients.
Daraxonrasib is the name of a drug for pancreas cancer that almost doubled survival for people with the disease in a clinical trial. William Nelson, director of the Kimmel Cancer Center at Johns Hopkins, says while the drug is going … A new drug for pancreas cancer may be a game changer, Elizabeth Tracey reports Read More »
More episodes of Health Newsfeed – Johns Hopkins Medicine Podcasts
- An AI model may help predict who is more likely to develop pancreas cancer, Elizabeth Tracey reports
- Will GLP1 drugs tease out the relationship between insulin and cancer? Elizabeth Tracey reports
- Is there a relationship between diet, obesity and colorectal cancer? Elizabeth Tracey reports
- What accounts for increases in colorectal cancer among younger people? Elizabeth Tracey reports
- A new drug for pancreas cancer may be a game changer, Elizabeth Tracey reports
- Certain groups of people seem to be missing out when it comes to optimizing cardiovascular disease prevention, Elizabeth Tracey reports
Explore listener stats, chart rankings, contacts and more on the Health Newsfeed – Johns Hopkins Medicine Podcasts podcast page.